Asset
VOLAMCABTAGENE DURZIGEDLEUCEL
CRISPR Therapeutics AG Common Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04438083 | phase1 | terminated | 2020-06-16 | 2024-10-08 | CRISPR Therapeutics AG | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC) |
| NCT04502446 | phase1 | terminated | 2020-07-31 | 2024-08-30 | CRISPR Therapeutics AG | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) |
FDA applications (0)
This company has no applications containing this asset.